Company Overview and News

2
SGRY / Surgery Partners, Inc. 8-K (Current Report)

2018-08-31 sec.gov - 2
UNITED STATES<
SGRY

 
Surgery Partners, Inc. (SGRY) CEO Wayne DeVeydt on Q2 2018 Results - Earnings Call Transcript

2018-08-11 seekingalpha
Greetings, and welcome to Surgery Partners Second Quarter 2018 Earnings Call. [Operator Instructions]. As a reminder, this conference is being recorded.
SGRY

27
Global Medical REIT (GMRE) Q2 FFO Meet Estimates

2018-08-09 zacks
Global Medical REIT (GMRE - Free Report) came out with quarterly funds from operations (FFO) of $0.20 per share, in line with the Zacks Consensus Estimate. This compares to FFO of $0.14 per share a year ago. These figures are adjusted for non-recurring items.
LSXMB SGRY GD BATRK FWONB LSXMA BATRR FWONA GMRE FWONK BATRB LSXMK PLUG BATRA

26
Surgery Partners (SGRY) Reports Q2 Loss, Tops Revenue Estimates

2018-08-09 zacks
Surgery Partners (SGRY - Free Report) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items.
SGRY GD BSTC PLUG

 
Surgery Partners, Inc. Announces Second Quarter 2018 Earnings Release Date and Conference Call Details

2018-07-26 globenewswire
NASHVILLE, Tenn., July 26, 2018 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading provider of surgical services, today announced that the Company will release its second quarter 2018 results before the market open on Thursday, August 9, 2018, to be followed by a conference call at 8:30 a.m. (Eastern Time)
SGRY

30
TransEnterix Stock Rose 5.6% on Friday and Early on June 4

2018-06-04 marketrealist
TransEnterix (TRXC) is a US-based medical device company that focuses on digitizing the interfaces between the surgeon and the patient. The stock price increased ~5.6% and closed at $3.75 on June 1. The stock rose ~3.2% to $3.87 in the pre-market session on June 4.
SGRY FATE UTMD SPSM

14
SGRY / Surgery Partners, Inc. 8-K (Current Report)

2018-05-18 sec.gov - 6
UNITED STATES<
SGRY

8
Surgery Partners, Inc. to Present at Upcoming Investor Conferences

2018-05-11 globenewswire
NASHVILLE, Tenn., May 11, 2018 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners”), a leading healthcare services company, today announced that management will present at the following conferences:
SGRY

8
Surgery Partners' (SGRY) CEO Wayne DeVeydt on Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Greetings, and welcome to the Surgery Partners Inc. First Quarter 2018 Earnings Conference Call. At this time, all participants will be in a listen only mode. A question and answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
SGRY

8
Surgery Partners, Inc. Announces First Quarter 2018 Results

2018-05-09 globenewswire
BRENTWOOD, Tenn., May 09, 2018 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading provider of surgical services, today announced results for the first quarter ended March 31, 2018.
SGRY

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 86881A100